Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Hiroshi Kuriki
Corrigendum to “Analysis of Central Nervous System Efficacy in the J-Alex Study of Alectinib Versus Crizotinib in ALK-positive Non-Small-Cell Lung Cancer” [Lung Cancer 121 (July) (2018) Pages 37–40]
Lung Cancer
Cancer Research
Oncology
Respiratory Medicine
Pulmonary
Related publications
Alectinib in ALK -Positive, Crizotinib-Resistant, Non-Small-Cell Lung Cancer: A Single-Group, Multicentre, Phase 2 Trial
The Lancet Oncology
Oncology
The Central Nervous System as a Sanctuary Site in ALK-Positive Non–Small-Cell Lung Cancer
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
How Should We Treat Alectinib-Refractory ALK-Positive Non–Small Cell Lung Cancer?
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Differential Crizotinib Response Duration Among ALK Fusion Variants in ALK-Positive Non–Small-Cell Lung Cancer
Journal of Clinical Oncology
Cancer Research
Medicine
Oncology
Economic Impact of Preventing Brain Metastases With Alectinib in ALK-positive Non-Small Cell Lung Cancer
Lung Cancer
Cancer Research
Oncology
Respiratory Medicine
Pulmonary
Heterogeneous Responses and Resistant Mechanisms to Crizotinib in ALK -Positive Advanced Non-Small Cell Lung Cancer
Thoracic Cancer
Medicine
Pulmonary
Respiratory Medicine
Oncology
Efficacy and Safety of Crizotinib Among Chinese EML4-ALK-Positive, Advanced-Stage Non-Small Cell Lung Cancer Patients
PLoS ONE
Multidisciplinary
Chinese Perspectives on Clinical Efficacy and Safety of Alectinib in Patients With ALK-positive Advanced Non-Small Cell Lung Cancer
OncoTargets and Therapy
Oncology
Pharmacology
Alectinib in Untreated Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer
Annals of Translational Medicine
Medicine
